Camurus

Camurus is a fully integrated, commercial-stage biopharma focused on transforming chronic disease management through its proprietary FluidCrystal® long-acting injectable technology. The company has achieved commercial success with Buvidal® for opioid dependence and is advancing a diversified pipeline in pain, oncology, and endocrinology through a dual strategy of in-house development and strategic partnerships. With a validated platform, established commercial infrastructure in key markets, and a streamlined development model, Camurus is positioned to deliver significant value to patients, healthcare systems, and shareholders.

Proprietary FluidCrystal® drug delivery platform for developing long-acting injectable and implantable depot formulations based on lipid-based liquid crystal structures that provide controlled release from one week to several months.

Camurus competes with large pharma in chronic disease markets but is defended by its patented FluidCrystal® platform. In opioid dependence, it holds a first-mover advantage with a flexible dosing regimen. For pipeline assets, competition is based on improving convenience and performance over existing long-acting injectables.